Telix Pharmaceuticals Limited
TLX
$10.67
-$0.07-0.65%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 803.79M | 735.55M | 667.30M | 594.97M | 514.88M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 803.79M | 735.55M | 667.30M | 594.97M | 514.88M |
| Cost of Revenue | 421.95M | 364.38M | 306.81M | 257.56M | 196.49M |
| Gross Profit | 381.85M | 371.17M | 360.49M | 337.41M | 318.39M |
| SG&A Expenses | 192.56M | 180.49M | 168.43M | 153.21M | 135.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.25M | -339.50K | 567.00K | -1.39M | 135.10K |
| Total Operating Expenses | 784.51M | 707.20M | 629.89M | 552.48M | 459.27M |
| Operating Income | 19.29M | 28.35M | 37.41M | 42.49M | 55.61M |
| Income Before Tax | -5.27M | 2.47M | 10.21M | 18.46M | 37.67M |
| Income Tax Expenses | 1.86M | 131.50K | -1.60M | -2.09M | 4.16M |
| Earnings from Continuing Operations | -7.13 | 2.34 | 11.80 | 20.55 | 33.51 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.13M | 2.34M | 11.80M | 20.55M | 33.51M |
| EBIT | 19.29M | 28.35M | 37.41M | 42.49M | 55.61M |
| EBITDA | 32.46M | 39.10M | 45.75M | 48.90M | 59.35M |
| EPS Basic | -0.02 | 0.03 | 0.08 | 0.09 | 0.13 |
| Normalized Basic EPS | -0.03 | 0.03 | 0.09 | 0.10 | 0.13 |
| EPS Diluted | -0.02 | 0.02 | 0.07 | 0.09 | 0.12 |
| Normalized Diluted EPS | -0.03 | 0.03 | 0.08 | 0.09 | 0.13 |
| Average Basic Shares Outstanding | 1.35B | 1.18B | 1.02B | 1.34B | 1.32B |
| Average Diluted Shares Outstanding | 1.35B | 1.20B | 1.04B | 1.39B | 1.38B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |